Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc8.1 | Oral Communications 8: Calcium and Bone | ECE2022

Effectiveness of anti-resorptive drugs on risk of vertebral fractures in women receiving aromatase inhibitors: a prospective study in real-life clinical practice

Mazziotti Gherardo , Vena Walter , Pigni Stella , Carrone Flaminia , Pedersini Rebecca , Cosentini Deborah , Torrisi Rosalba , Birtolo Maria Francesca , Maida Giulia , Berruti Alfredo , Lania Andrea

Bone loss is a frequent complication of aromatase inhibitors (AIs) therapy in women with breast cancer. Bone-active drugs are effective in protecting the skeleton from detrimental actions of AIs. However, bone mineral density (BMD) was the primary end-point in most of published studies, whereas data on fractures were scant and mainly limited to denosumab. In this prospective study, we investigated the effects of denosumab, oral bisphosphonates and intravenous zoledronate on ri...

ea0081rc3.7 | Rapid Communications 3: Thyroid 1 | ECE2022

Immune-related thyroid dysfunctions during PD-1/PD-L1 inhibitors and their association to the oncological outcome: new evidence

Ferrari Matteo , Anna Nervo Alice , Basile Sara , Migliore Enrica , D'Angelo Valentina , Gruosso Giovanni , Rosso Daniela , Retta Francesca , Piovesan Alessandro , Arvat Emanuela

Background: Immune checkpoint inhibitors (ICIs) showed impressive results in several malignancies; however, a large spectrum of immune-related adverse events (IRAEs) may occur, including thyroid dysfunction (DYSTHYR). IRAEs seem to be associated with better cancer outcome; limited data suggested that thyroid toxicity could be a predictor of response to ICIs.Patients and methods: We retrospectively evaluated all patients who started treatment with the pro...

ea0081rc4.1 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Immunotherapy in a non-functioning metastatic pituitary neuroendocrine tumor. An encouraging case report

Feola Tiziana , Gianno Francesca , Verrico Monica , Giangaspero Felice , Tomao Silverio , Colonnese Claudio , Esposito Vincenzo , Isidori Andrea , Minniti Giuseppe , Jaffrain-Rea Marie-Lise

Introduction: Metastatic pituitary neuroendocrine tumors (PitNETs) or pituitary carcinomas are rare and challenging conditions. We present a recent and encouraging observation of a temozolomide (TMZ)-resistant clinically non-functioning metastatic PitNET showing a remarkable response to the anti-PDL1 drug Pembrolizumab.Case presentation: A 57-years-old man had transsphenoidal surgery in November 2012 for a large non-functioning intra/suprasellar mass rev...

ea0081p16 | Adrenal and Cardiovascular Endocrinology | ECE2022

Prevalence and clinical features of ARMC5 mutations in a single centre cohort of patients with bilateral adrenal incidentalomas

Frigerio Sofia , Morelli Valentina , Marta Elli Francesca , Vena Walter , Maffini Maria Antonia , Lucca Camilla , Piu Matteo , Mora Nicola , Palmieri Serena , Mantovani Giovanna , Arosio Maura

Introduction: Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare cause of Cushing’s syndrome (CS). Some familial forms have been associated to gene ARMC5 (Armadillo repeat-containing protein 5) inactivating mutations. This study aimed to evaluate the prevalence and the complications of ARMC5 mutations in our cohort of patients with bilateral adrenal incidentalomas (BAI).Methods: 72 patients, referred to our Center...

ea0081p298 | Calcium and Bone | ECE2022

Evaluation of pth deprivation effects on spatial memory in a rat model of chronic post-surgical Hypoparathyroidism

Saponaro Federica , Ronca Francesca , Dettori Cristina , Frascarelli Sabina , Di Buono Giulia , Giacomelli Silvia , Chiellini Grazia , Scalese Marco , Cetani Filomena , Marcocci Claudio , Zucchi Riccardo

Introduction: Hypoparathyroidism (HypoPT) is a rare endocrine disease which is characterized by hypocalcaemia and undetectable or inappropriately low serum parathyroid hormone (PTH). Post-surgical HypoPT (PS-HypoPT) is the most common cause, caused by accidental parathyroid removal/injury during neck surgery. Conventional therapy with calcium and vitamin D analogues does not restore calcium homeostasis and patients with chronic PS-HypoPT complain with several complications. Fr...

ea0081p390 | Endocrine-Related Cancer | ECE2022

Uncovering the immune profile in well-differentiated gastroenteropancreatic neuroendocrine tumors

Sesti Franz , Puliani Giulia , Sciarra Francesca , Feola Tiziana , Centello Roberta , Di Vito Valentina , Pandozzi Carla , Lenzi Andrea , Isidori Andrea , Venneri Mary Anna , Faggiano Antongiulio , Giannetta Elisa

Introduction: Immune tumor microenvironment plays a key role in tumors’ growth and metastatic spread, while its role in the heterogeneous field of neuroendocrine neoplasms (NENs) remains unclear. There is evidence that tumor progression in NENs is promoted by an immunosuppressed microenvironment created by a plethora of infiltrating immune cells. Changes in circulating leukocyte and peripheral blood mononuclear cell (PBMC) subpopulations can mirror the local alteration of...

ea0081p401 | Pituitary and Neuroendocrinology | ECE2022

Prevalence, type and evolution of autoimmune diseases with respect to hormone control in patients with cortisol, GH and prolactin hypersecretion

Guaraldi Federica , Zoli Matteo , Arvat Emanuela , De Martin Martina , Pecori Giraldi Francesca , Carla Scaroni , Gori Davide , GIORDANO Roberta , Grottoli Silvia , Ghigo Ezio , Asioli Sofia , Mazzatenta Diego

Background: In vitro and animal experiments have clearly demonstrated that excessive cortisol, GH and prolactin secretion, as well as dopamine agonists (D2As) and somatostatin analogs (SSAs), often prescribed for their treatment, affect the immune response and the onset/evolution of autoimmune diseases (AIDs) through direct and indirect complex mechanisms. Data from clinical studies are very scanty.Study aim: To assess the 1) distribution of AIDs accordi...

ea0081p673 | Pituitary and Neuroendocrinology | ECE2022

Transition in endocrinology: predictors of drop-out in a heterogeneous population during long-term follow-up

Romanisio Martina , Brasili Sara , Daffara Tommaso , Ferrero Alice , Vimercati Davide , Pizzolitto Francesca , Pitino Rosa , Luigi Maria Mollero Edoardo , Zavattaro Marco , Bellone Simonetta , Caputo Marina , Aimaretti Gianluca , Prodam Flavia

Aim: To evaluate: 1) clinical and epidemiological characteristics of outpatients transitioned from Pediatrics Endocrine (PED) to Adult Endocrine Department (AED) in a tertiary Centre; 2) transition process characteristics, and predictive factors of drop-out.Patients and methods: Demographic, clinical, and transition features of 170 consecutive patients with paediatric onset of chronic endocrine or metabolic disease (excluded type 1 diabetes) who transiti...

ea0081ep1138 | Thyroid | ECE2022

Autoimmune thyroiditis and hypothyroidism: a personalized medical approach

Martina Ferrari Silvia , Ragusa Francesca , Elia Giusy , Paparo Sabrina Rosaria , Mazzi Valeria , Balestri Eugenia , Botrini Chiara , Patrizio Armando , Antonelli Alessandro , Fallahi Poupak

Autoimmune thyroid diseases (AITD) are organ specific autoimmune disorders with a T-cell-mediated immune attack directed against the thyroid. Hashimoto’s thyroiditis and Graves’ disease are the two principal AITD clinical presentations, which are characterized by hypothyroidism and thyrotoxicosis, respectively. We review the available data in literature about personalized medicine in patients with autoimmune thyroiditis (AT) and hypothyroidism. The synthetic Levothyr...

ea0084ps1-03-20 | Thyroid Cancer CLINICAL 1 | ETA2022

Changes in clinical status after second 131I treatment in patients with differentiated thyroid cancer (dtc) not cured with the initial treatment

Gambale Carla , Matrone Antonio , Bottaro Valeria , Prete Alessandro , Faranda Alessio , Contartese Lea , Bianchi Francesca , Torregrossa Liborio , Basolo Fulvio , Molinaro Eleonora , Elisei Rossella

Objectives: Currently 131I treatment after surgery is suggested in selected intermediate-risk and in high-risk patients with DTC. In patients with radio-avid structural disease and in those with biochemical disease a second 131I treatment could be considered. However data about the impact of the second 131I treatment on clinical status remains controversial.Methods: Clinical data of 231 DTC patients followed at the Unit o...